Next Generation Immunotherapies Global Market Report 2025

Description

Next-generation immunotherapies are advanced treatments designed to enhance the body's immune system to combat diseases, particularly cancer, with greater precision, efficacy, and safety. These therapies surpass traditional immune-based treatments by utilizing cutting-edge technologies to overcome previous limitations, minimize side effects, and provide long-lasting immune responses.

The primary drug classes in next-generation immunotherapies include monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are lab-engineered proteins that precisely target specific antigens, boosting immune response and treatment effectiveness. These drugs are administered through various routes, such as intravenous, parenteral, intratumoral, subcutaneous, and oral. They are distributed through multiple channels, including hospital pharmacies, clinical pharmacies, and other distribution networks.

The next-generation immunotherapies market research report is one of a series of new reports from The Business Research Company that provides next-generation immunotherapies market statistics, including the next-generation immunotherapies industry global market size, regional shares, competitors with the next-generation immunotherapies market share, detailed next-generation immunotherapies market segments, market trends, and opportunities, and any further data you may need to thrive in the next-generation immunotherapies industry. This next-generation immunotherapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $133.81 billion in 2024 to $150.54 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period can be attributed to the increasing prevalence of oncology, higher investments in research and development, rising government initiatives, increased healthcare expenditures, and the expanding range of indications for immunotherapies.

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $238.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to the rising prevalence of cancer, increasing healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) T-cell therapy, a higher burden of chronic diseases, and expanding research in next-generation drugs. Key trends in the forecast period include a shift toward combination therapies, technological advancements, innovations in therapeutic approaches, progress in personalized medicine, and enhanced regulatory support.

The growing prevalence of cancer is expected to drive the expansion of the next-generation immunotherapies market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing incidence of cancer, including aging populations, lifestyle changes, environmental exposures, and advancements in detection methods. Next-generation immunotherapies offer advanced, targeted treatments that enhance the body's immune response to cancer, providing improved effectiveness, durability, and personalization. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation immunotherapies market.

Leading companies in the next-generation immunotherapies market are focusing on the development of innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is an advanced immunotherapy technique in which a patient's T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India's first CAR T-cell therapy. This treatment targets adult B-cell non-Hodgkin lymphoma by genetically modifying a patient's immune cells to recognize and eliminate cancer cells, offering a highly effective and personalized approach. It presents new hope for patients who have not responded to conventional treatments, with the added benefit of being more cost-effective than similar international options.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition is part of Coherus BioSciences' strategy to expand its immuno-oncology portfolio by developing novel therapies that target the tumor microenvironment to enhance cancer treatment. Surface Oncology Inc., a US-based immuno-oncology company, specializes in next-generation immunotherapies designed to modify the tumor microenvironment for improved treatment outcomes.

Major players in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Next Generation Immunotherapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Immunotherapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation immunotherapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation immunotherapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation immunotherapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Monoclonal Antibodies; Antibody-Drug Conjugates - ADC's; Angiotensin-Converting Enzyme (ACE) Inhibitors; Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous; Parenteral; Intratumoral; Subcutaneous; Oral
3) By Distribution Channel: Hospital Pharmacies; Clinical Pharmacies; Other Distribution channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies; Anti-PD-L1 Antibodies; Anti-CTLA-4 Antibodies; Anti-CD20 Antibodies; Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs; CD30-targeted ADCs; CD19-targeted ADCs; Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy; ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Other Immune Checkpoint Inhibitors
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34097

1. Executive Summary

2. Next Generation Immunotherapies Market Characteristics

3. Next Generation Immunotherapies Market Trends And Strategies

4. Next Generation Immunotherapies Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Next Generation Immunotherapies Growth Analysis And Strategic Analysis Framework

5.1. Global Next Generation Immunotherapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Next Generation Immunotherapies Market Growth Rate Analysis
5.4. Global Next Generation Immunotherapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Next Generation Immunotherapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Next Generation Immunotherapies Total Addressable Market (TAM)

6. Next Generation Immunotherapies Market Segmentation

6.1. Global Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Antibody-Drug Conjugates - ADC's
Angiotensin-Converting Enzyme (ACE) Inhibitors
Immune Checkpoint Inhibitors
6.2. Global Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Parenteral
Intratumoral
Subcutaneous
Oral
6.3. Global Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Clinical Pharmacies
Other Distribution channels
6.4. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-PD-1 Antibodies
Anti-PD-L1 Antibodies
Anti-CTLA-4 Antibodies
Anti-CD20 Antibodies
Other Monoclonal Antibodies
6.5. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADC's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HER2-targeted ADCs
CD30-targeted ADCs
CD19-targeted ADCs
Other ADCs
6.6. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
ACE Inhibitors For Cancer Therapy
ACE Inhibitors For Other Indications
6.7. Global Next Generation Immunotherapies Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PD-1 Or PD-L1 Inhibitors
CTLA-4 Inhibitors
Other Immune Checkpoint Inhibitors

7. Next Generation Immunotherapies Market Regional And Country Analysis

7.1. Global Next Generation Immunotherapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Next Generation Immunotherapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Immunotherapies Market

8.1. Asia-Pacific Next Generation Immunotherapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Immunotherapies Market

9.1. China Next Generation Immunotherapies Market Overview
9.2. China Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Immunotherapies Market

10.1. India Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Immunotherapies Market

11.1. Japan Next Generation Immunotherapies Market Overview
11.2. Japan Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Immunotherapies Market

12.1. Australia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Immunotherapies Market

13.1. Indonesia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Immunotherapies Market

14.1. South Korea Next Generation Immunotherapies Market Overview
14.2. South Korea Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Immunotherapies Market

15.1. Western Europe Next Generation Immunotherapies Market Overview
15.2. Western Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Immunotherapies Market

16.1. UK Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Immunotherapies Market

17.1. Germany Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Immunotherapies Market

18.1. France Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Immunotherapies Market

19.1. Italy Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Immunotherapies Market

20.1. Spain Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Immunotherapies Market

21.1. Eastern Europe Next Generation Immunotherapies Market Overview
21.2. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Immunotherapies Market

22.1. Russia Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Immunotherapies Market

23.1. North America Next Generation Immunotherapies Market Overview
23.2. North America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Immunotherapies Market

24.1. USA Next Generation Immunotherapies Market Overview
24.2. USA Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Immunotherapies Market

25.1. Canada Next Generation Immunotherapies Market Overview
25.2. Canada Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Immunotherapies Market

26.1. South America Next Generation Immunotherapies Market Overview
26.2. South America Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Immunotherapies Market

27.1. Brazil Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Immunotherapies Market

28.1. Middle East Next Generation Immunotherapies Market Overview
28.2. Middle East Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Immunotherapies Market

29.1. Africa Next Generation Immunotherapies Market Overview
29.2. Africa Next Generation Immunotherapies Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Next Generation Immunotherapies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Next Generation Immunotherapies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Immunotherapies Market Competitive Landscape And Company Profiles

30.1. Next Generation Immunotherapies Market Competitive Landscape
30.2. Next Generation Immunotherapies Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Immunotherapies Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca PLC
31.3. Novartis AG
31.4. GlaxoSmithKline plc (GSK)
31.5. Eli Lilly and Company
31.6. Gilead Sciences Inc.
31.7. Amgen Inc.
31.8. Boehringer Ingelheim International GmbH
31.9. Regeneron Pharmaceuticals Inc.
31.10. Incyte Corporation
31.11. BioNTech SE
31.12. Xencor Inc.
31.13. Fate Therapeutics Inc.
31.14. Immatics N.V.
31.15. Atara Biotherapeutics Inc.

32. Global Next Generation Immunotherapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Immunotherapies Market

34. Recent Developments In The Next Generation Immunotherapies Market

35. Next Generation Immunotherapies Market High Potential Countries, Segments and Strategies

35.1 Next Generation Immunotherapies Market In 2029 - Countries Offering Most New Opportunities
35.2 Next Generation Immunotherapies Market In 2029 - Segments Offering Most New Opportunities
35.3 Next Generation Immunotherapies Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer